Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT05995028
PHASE1

Universal 4SCAR7U Targeting CD7-positive Malignancies

Sponsor: Shenzhen Geno-Immune Medical Institute

View on ClinicalTrials.gov

Summary

The purpose of this clinical trial is to assess the feasibility, safety and efficacy of universal CAR T cells based on 4SCAR7U design against CD7-positive hematological malignancies using CD7 specific universal CAR T cells. The study also aims to learn more about the function of CD7 targeting CAR T cells and their persistence in patients of hematological malignancies.

Official title: Safety and Efficacy of Universal 4SCAR7U T Cell Therapy Targeting CD7-positive Hematological Malignancies

Key Details

Gender

All

Age Range

6 Months - 75 Years

Study Type

INTERVENTIONAL

Enrollment

30

Start Date

2023-10-31

Completion Date

2026-12-31

Last Updated

2023-10-12

Healthy Volunteers

No

Interventions

BIOLOGICAL

Universal CD7-specific CAR gene-engineered T cells

Infusion of 4SCAR7U T cells

Locations (1)

Shenzhen Geno-immune Medical Institute

Shenzhen, Guangdong, China